Terms: = Thyroid cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Staging
37 results:
1. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary thyroid cancer.
Gild ML; Kumar S; Fuchs TL; Glover A; Sidhu S; Sywak M; Tsang V; Gill AJ; Robinson BG; Schembri G; Clifton-Bligh RJ; Hoang J
Endocr Pract; 2024 Mar; 30(3):218-224. PubMed ID: 38103829
[TBL] [Abstract] [Full Text] [Related]
2. Medullary thyroid carcinoma.
Pelizzo MR; Mazza EI; Mian C; Merante Boschin I
Expert Rev Anticancer Ther; 2023; 23(9):943-957. PubMed ID: 37646181
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Evolution of Sporadic Medullary thyroid Carcinoma With Biochemical Incomplete Response After Initial Treatment.
Prete A; Gambale C; Torregrossa L; Ciampi R; Romei C; Ramone T; Agate L; Bottici V; Cappagli V; Molinaro E; Materazzi G; Elisei R; Matrone A
J Clin Endocrinol Metab; 2023 Jul; 108(8):e613-e622. PubMed ID: 36722192
[TBL] [Abstract] [Full Text] [Related]
4. thyroidectomy Outcomes in Patients Identified With ret Pathogenic Variants Through a Population Genomic Screening Program.
Pichardo PFA; Hellums RN; Hao J; Savatt JM; Hassen D; Pellitteri PK; Alvi M; Buchanan AH; Purdy NC
JAMA Otolaryngol Head Neck Surg; 2023 Mar; 149(3):195-202. PubMed ID: 36602781
[TBL] [Abstract] [Full Text] [Related]
5. The correlation between the expression of ATF4 and procalcitonin combined with the detection of
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Can J Physiol Pharmacol; 2022 Jan; 100(1):19-25. PubMed ID: 34822305
[TBL] [Abstract] [Full Text] [Related]
6. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings.
Khanna L; Prasad SR; Yedururi S; Parameswaran AM; Marcal LP; Sandrasegaran K; Tirumani SH; Menias CO; Katabathina VS
Radiographics; 2021; 41(3):876-894. PubMed ID: 33891523
[TBL] [Abstract] [Full Text] [Related]
7. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M; Trocchianesi S; Besharat ZM; Po A; Ferretti E
Pharmacol Ther; 2021 Mar; 219():107708. PubMed ID: 33091426
[TBL] [Abstract] [Full Text] [Related]
8. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
[TBL] [Abstract] [Full Text] [Related]
9. Protean cytological, histological and immunohistochemical appearances of medullary thyroid carcinoma: current updates.
Buzdugă CM; Costea CF; Cărăuleanu A; Lozneanu L; Turliuc MD; Cucu AI; Ciocoiu M; Floria M; Tănase DM; Dragomir RA; Haba RM; Dumitrescu AM; Bogdănici CM; Ciobanu Apostol DG
Rom J Morphol Embryol; 2019; 60(2):369-381. PubMed ID: 31658309
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Markers Involved in Tumorigenesis of thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract] [Full Text] [Related]
11. A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic ret mutation.
Chuang LL; Hwang DY; Tsai KB; Chan HM; Chiang FY; Hsiao PJ
Kaohsiung J Med Sci; 2016 Nov; 32(11):545-551. PubMed ID: 27847096
[TBL] [Abstract] [Full Text] [Related]
12. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract] [Full Text] [Related]
13. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract] [Full Text] [Related]
14. Long-Term Follow-up in Medullary thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract] [Full Text] [Related]
15. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma.
Costa V; Esposito R; Ziviello C; Sepe R; Bim LV; Cacciola NA; Decaussin-Petrucci M; Pallante P; Fusco A; Ciccodicola A
Oncotarget; 2015 May; 6(13):11242-51. PubMed ID: 25803323
[TBL] [Abstract] [Full Text] [Related]
16. Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.
Russo E; Salzano M; De Falco V; Mian C; Barollo S; Secondo A; Bifulco M; Vitale M
Clin Cancer Res; 2014 Mar; 20(6):1513-20. PubMed ID: 24449826
[TBL] [Abstract] [Full Text] [Related]
17. Concomitant BRAF(V600E) mutation and ret/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract] [Full Text] [Related]
18. The clinical spectrum of ret proto-oncogene mutations in codon 790.
Bihan H; Murat A; Fysekidis M; Al-Salameh A; Schwartz C; Baudin E; Thieblot P; Borson-Chazot F; Guillausseau PJ; Cardot-Bauters C; Raingeard I; Requeda E; Sadoul JL; Reznik Y;
Eur J Endocrinol; 2013 Sep; 169(3):271-6. PubMed ID: 23756355
[TBL] [Abstract] [Full Text] [Related]
19. ret proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China.
Qi XP; Chen XL; Ma JM; Du ZF; Fei J; Yang CP; Cheng J; Song QZ; Han JS; Jin HY; Chen ZG; Wang JQ; Yang YP; Ying RB; Liu WT; Zhao Y; Chen CY; Jiang HL; Ke HP; Zhang XN
Thyroid; 2012 Dec; 22(12):1257-65. PubMed ID: 23210566
[TBL] [Abstract] [Full Text] [Related]
20. Role of prophylactic thyroidectomy in ret 790 familial medullary thyroid carcinoma.
Bihan H; Baudin E; Meas T; Leboulleux S; Al Ghuzlan A; Hannoteaux V; Travagli JP; Valleur P; Guillausseau PJ; Cohen R;
Head Neck; 2012 Apr; 34(4):493-8. PubMed ID: 21688339
[TBL] [Abstract] [Full Text] [Related]
[Next]
